Alicia C. Olivo's most recent trade in Neogenomics Inc. was a trade of 1,666 Common Stock done . Disclosure was reported to the exchange on Sept. 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Neogenomics Inc. | Alicia C. Olivo | EVP, GC & Business Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Sep 2025 | 1,666 | 47,940 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | Alicia C. Olivo | EVP, GC & Business Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Aug 2025 | 14 | 49,606 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | Alicia C. Olivo | EVP, GC & Business Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2025 | 6,503 | 6,503 | - | - | Restricted Stock Unit | |
| Neogenomics Inc. | Alicia C. Olivo | EVP, GC & Business Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2025 | 6,503 | 51,204 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | Alicia C. Olivo | EVP, GC & Business Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 11 May 2025 | 1,584 | 49,620 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | Alicia C. Olivo | EVP, GC & Business Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 May 2025 | 652 | 44,701 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | Alicia C. Olivo | EVP, GC & Business Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 107,450 | 107,450 | - | - | Stock Option (Right to Buy) | |
| Neogenomics Inc. | Alicia C. Olivo | EVP, GC & Business Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 63,238 | 63,238 | - | - | Restricted Stock Unit | |
| Neogenomics Inc. | Alicia C. Olivo | EVP, GC & Business Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2025 | 8,443 | 47,857 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | Alicia C. Olivo | EVP, GC & Business Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2025 | 8,443 | 16,886 | - | - | Restricted Stock Unit | |
| Neogenomics Inc. | Alicia C. Olivo | EVP, GC & Business Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 21 Feb 2025 | 2,504 | 45,353 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | Alicia C. Olivo | EVP, GC & Business Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2025 | 59,382 | 59,382 | - | - | Restricted Stock Unit | |
| Neogenomics Inc. | Alicia C. Olivo | General Counsel | Sale of securities on an exchange or to another person at price $ 15.36 per share. | 15 Nov 2024 | 5,175 | 37,129 (0%) | 0% | 15.4 | 79,475 | Common Stock |
| Neogenomics Inc. | Alicia C. Olivo | General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Sep 2024 | 1,666 | 42,147 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | Alicia C. Olivo | General Counsel | Sale of securities on an exchange or to another person at price $ 16.05 per share. | 15 Aug 2024 | 1,040 | 43,813 (0%) | 0% | 16.1 | 16,695 | Common Stock |
| Neogenomics Inc. | Alicia C. Olivo | General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Aug 2024 | 14 | 44,853 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | Alicia C. Olivo | General Counsel | Sale of securities on an exchange or to another person at price $ 15.74 per share. | 15 May 2024 | 1,049 | 44,867 (0%) | 0% | 15.7 | 16,511 | Common Stock |
| Neogenomics Inc. | Alicia C. Olivo | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2024 | 6,502 | 13,006 | - | - | Restricted Stock Unit | |
| Neogenomics Inc. | Alicia C. Olivo | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2024 | 6,502 | 45,916 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | Alicia C. Olivo | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2024 | 6,502 | 40,998 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | Alicia C. Olivo | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2024 | 6,502 | 40,998 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | Alicia C. Olivo | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2024 | 6,502 | 13,006 | - | - | Restricted Stock Unit | |
| Neogenomics Inc. | Alicia C. Olivo | General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.86 per share. | 11 May 2024 | 1,584 | 39,414 (0%) | 0% | 14.9 | 23,538 | Common Stock |
| Neogenomics Inc. | Alicia C. Olivo | General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.86 per share. | 11 May 2024 | 1,584 | 39,414 (0%) | 0% | 14.9 | 23,538 | Common Stock |
| Neogenomics Inc. | Alicia C. Olivo | General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 May 2024 | 652 | 34,496 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | C. Alicia Olivo | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 42,344 | 42,344 | - | - | Stock Option (Right to Buy) | |
| Neogenomics Inc. | Olivo C. Alicia | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 25,330 | 25,330 | - | - | Performance Stock Unit | |
| Neogenomics Inc. | Olivo Alicia C. | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 25,329 | 25,329 | - | - | Restricted Stock Unit | |
| Neogenomics Inc. | Alicia Olivo C. | General Counsel | Sale of securities on an exchange or to another person at price $ 14.96 per share. | 15 Feb 2024 | 2,587 | 34,866 (0%) | 0% | 15.0 | 38,713 | Common Stock |
| Neogenomics Inc. | Alicia C. Olivo | General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Aug 2023 | 14 | 40,981 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | Alicia C. Olivo | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2023 | 36,508 | 36,508 | - | - | Stock Option (Right to Buy) | |
| Neogenomics Inc. | Alicia C. Olivo | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2023 | 19,508 | 19,508 | - | - | Performance Stock Unit | |
| Neogenomics Inc. | Alicia C. Olivo | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2023 | 19,508 | 19,508 | - | - | Restricted Stock Unit | |
| Neogenomics Inc. | Alicia C. Olivo | General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 May 2023 | 662 | 40,694 (0%) | 0% | 0 | Common Stock |